Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Double-blind, Placebo-controlled Study of Namilumab in Chronic Pulmonary Sarcoidosis
2021-004794-31Phase 2Active
- Sponsor
- Kinevant Sciences
- Start
- Apr 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in pulmonary sarcoidosis comparing Namilumab arm with Placebo arm (2 arms). Primary endpoint: Proportion of subjects requiring rescue treatment for worsening of sarcoidosis. Started Apr 2022; status: active.
02
Drugs
namilumab
03
Conditions
pulmonary sarcoidosis
Beyond the preview
Go deeper on 2021-004794-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004794-31.